- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Cystic Fibrosis
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Arginase Inhibitor
Cystic Fibrosis - Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Sapanisertib
(CB-228)Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types.
NRF2-mutated lung cancer cells have been shown to be selectively more sensitive to dual TORC1/2 inhibitors both in vitro and in vivo. As a next-generation TORC inhibitor, sapanisertib provides dual inhibition of TORC 1 and 2, and in early clinical studies has demonstrated durable single-agent responses and clinical benefit in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (sqNSCLC), with a well-tolerated safety profile.
Sapanisertib is a clinically well-characterized next generation dual TORC1/2 inhibitor, including its safety profile, PK/PD relationship and monotherapy efficacy data.
More than 235,000 individuals are diagnosed with NSCLC in the US each year, and approximately 25-30% of these are sqNSCLC. KEAP1/NRF2 mutations are present in approximately 27% of these sqNSCLC patients’ tumors and confer a poorer prognosis than wild type NSCLC.
A Phase 2 study planned to begin in the first quarter of 2022 will further evaluate sapanisertib as a monotherapy in patients with squamous NSCLC harboring a NRF2 mutation, KEAP1 mutation, or wild-type NRF2/KEAP1.
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.